Darolutamide plus androgen-deprivation therapy in high-risk biochemical recurrence of prostate cancer (ARASTEP).

Morgans AK, Chehrazi-Raffle A, Niazi T, Shore ND, Ross AE, Røder A, Gomes AJ, Supiot S, Barthélémy P, Hatano K, Ruiz CBC, Yoshida S, Herrera-Imbroda B, Gratton M, Gschwend JE, Hope TA, Joensuu H, Kuss I, Le Berre MA, Dimova-Dobreva M, Fizazi K

Open source

DOI: 10.1080/14796694.2025.2577633
Published: 2025 Nov
Container: Future oncology (London, England)
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/14796694.2025.2577633,
  title = {Darolutamide plus androgen-deprivation therapy in high-risk biochemical recurrence of prostate cancer (ARASTEP).},
  author = {Morgans AK and Chehrazi-Raffle A and Niazi T and Shore ND and Ross AE and Røder A and Gomes AJ and Supiot S and Barthélémy P and Hatano K and Ruiz CBC and Yoshida S and Herrera-Imbroda B and Gratton M and Gschwend JE and Hope TA and Joensuu H and Kuss I and Le Berre MA and Dimova-Dobreva M and Fizazi K},
  year = {2025},
  journal = {Future oncology (London, England)},
  doi = {10.1080/14796694.2025.2577633},
  url = {https://doi.org/10.1080/14796694.2025.2577633}
}

RIS

TY  - JOUR
TI  - Darolutamide plus androgen-deprivation therapy in high-risk biochemical recurrence of prostate cancer (ARASTEP).
AU  - Morgans AK
AU  - Chehrazi-Raffle A
AU  - Niazi T
AU  - Shore ND
AU  - Ross AE
AU  - Røder A
AU  - Gomes AJ
AU  - Supiot S
AU  - Barthélémy P
AU  - Hatano K
AU  - Ruiz CBC
AU  - Yoshida S
AU  - Herrera-Imbroda B
AU  - Gratton M
AU  - Gschwend JE
AU  - Hope TA
AU  - Joensuu H
AU  - Kuss I
AU  - Le Berre MA
AU  - Dimova-Dobreva M
AU  - Fizazi K
PY  - 2025
JO  - Future oncology (London, England)
DO  - 10.1080/14796694.2025.2577633
UR  - https://doi.org/10.1080/14796694.2025.2577633
ER  -

APA

AK, M., A, C., T, N., ND, S., AE, R., A, R., AJ, G., S, S., P, B., K, H., CBC, R., S, Y., B, H., M, G., JE, G., TA, H., H, J., I, K., MA, L. B., M, D., & K, F. (2025). Darolutamide plus androgen-deprivation therapy in high-risk biochemical recurrence of prostate cancer (ARASTEP).. Future oncology (London, England). https://doi.org/10.1080/14796694.2025.2577633

Source records

pubmed · retrieved 2026-09-26T02:10:51.632Z